Welcome to our dedicated page for Sensus Healthcare SEC filings (Ticker: SRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating FDA milestones, clinical trial updates, and recurring revenue details inside Sensus Healthcare’s dense SEC documents can feel like dissecting a treatment manual. When a single 10-K hides segment margins for SRT device sales and a late-night 8-K moves the stock on new reimbursement codes, missing a line item could cost you clarity—or capital. Stock Titan solves this problem by distilling every Sensus Healthcare filing into plain-English highlights the moment it hits EDGAR.
Our AI-powered summaries cut through medical jargon so you immediately grasp how a fresh 10-Q affects device deployment trends or why an 8-K material event matters to future cash flow. Need real-time Sensus Healthcare Form 4 insider transactions? We alert you as executives buy or sell shares, helping you track Sensus Healthcare insider trading Form 4 transactions before the market reacts. Want the full picture? Access every form in one feed—10-K, 10-Q, 8-K, DEF 14A, and Section 16 filings—each tagged with expert notes, key metrics, and cross-links to historical data.
Whether you’re comparing quarter-over-quarter keloid treatment revenue, studying Sensus Healthcare proxy statement executive compensation, or just looking for a Sensus Healthcare annual report 10-K simplified, our platform answers the questions investors actually ask: "How do I read Sensus Healthcare’s earnings report filing analysis?" or "Where can I find Sensus Healthcare quarterly earnings report 10-Q filing?" From Sensus Healthcare 8-K material events explained to "understanding Sensus Healthcare SEC documents with AI," Stock Titan delivers comprehensive coverage and context so you can act with confidence.
Sensus Healthcare reported an insider stock grant to one of its leaders. Director and officer Michael Sardano, who serves as President and General Counsel, acquired 40,000 shares of common stock on 12/12/2025 through a restricted stock award under the Sensus Healthcare, Inc. 2017 Equity Incentive Plan.
The restricted shares will vest in four equal annual installments starting on the first anniversary of the grant date. Following this grant, Sardano directly beneficially owns 158,839 shares of Sensus Healthcare common stock, with an additional 1,000 shares held by his spouse, for which he disclaims beneficial ownership.
Sensus Healthcare, Inc. director and officer Michael Sardano filed an amended insider ownership report. The amendment clarifies that his spouse holds 1,000 shares of Sensus Healthcare common stock, which are reported as indirectly owned through his spouse.
The report states that Sardano disclaims beneficial ownership of these 1,000 shares, even though they are attributable to him for reporting purposes. This amendment corrects an earlier report that had shown no indirect ownership of the company’s common stock.
Sensus Healthcare, Inc. director reports open-market stock purchase. A company director filed a Form 4 disclosing the purchase of 7,000 shares of Sensus Healthcare common stock on 11/21/2025 at a price of $3.93 per share. Following this transaction, the director now beneficially owns 140,113 shares, held directly. The filing was made by a single reporting person in their capacity as a director of Sensus Healthcare.
Sensus Healthcare, Inc. (SRTS) reported an insider share purchase by a director. On 11/13/2025, the reporting person bought 2,500 shares of common stock in an open market transaction coded "P" at a price of $4.50 per share. After this transaction, the director beneficially owns 133,113 shares of Sensus Healthcare common stock, held directly. This filing reflects a change in insider ownership rather than an operating or financial update for the company.
Sensus Healthcare, Inc. (SRTS)130,613 shares of Sensus Healthcare common stock directly, reflecting personal holdings. In addition, the filing reports 2,093 shares of common stock held indirectly through the insider's spouse. The form is filed by a single reporting person and indicates the insider's status as a director of the company, with no derivative securities reported.
Sensus Healthcare, Inc. (SRTS) reported an insider stock purchase by its Chief Executive Officer and director, Joseph C. Sardano. On 11/18/2025, he acquired 25,000 shares of Sensus Healthcare common stock in an open-market purchase transaction coded "P" at an average price of $4.03 per share, as noted in the explanation that this figure represents the average price per share.
Following this transaction, Sardano beneficially owns 1,200,293 shares of Sensus Healthcare common stock in direct ownership. The filing is made on Form 4 as a report by one reporting person in his capacity as both director and Chief Executive Officer of the company.
Sensus Healthcare, Inc. (SRTS)11/18/2025, he acquired 1,000 shares of common stock at a price of $3.80 per share, coded as a purchase transaction. Following this trade, he now beneficially owns 118,839 shares of Sensus Healthcare common stock with direct ownership.
Sardano is listed as a Director and as an Officer with the title President and General Counsel, indicating both governance and executive responsibilities at the company. This filing is made on Form 4, which reports changes in ownership of the company’s equity securities by insiders.
Sensus Healthcare, Inc. insider Michael Sardano, who serves as President, General Counsel, and a director of the company, reported open-market purchases of SRTS common stock. On 11/11/2025, he bought 1,000 shares of common stock at a price of $4.26 per share, bringing his directly owned holdings to 117,839 shares.
On the same date, his spouse purchased 766 shares at $4.27 per share and 234 shares at $4.34 per share, for a total of 1,000 shares held in the spouse’s name. The filing notes that Sardano disclaims beneficial ownership of the shares held by his spouse.
Sensus Healthcare appointed Eric Sachetta as a Class II director, filling the vacancy created by the passing of William McCall. His term runs until the 2026 annual meeting. The Board determined he is an independent director under Nasdaq Rule 5605(a)(2), and he has been named to the Audit Committee.
Sachetta is Chief Wealth Services Officer of Sachetta, LLC and a Certified Financial Planner. He will receive the same pro rata compensation as other non‑employee directors. The company reported no arrangements or transactions requiring disclosure under Item 404(a).
Sensus Healthcare (SRTS) officer and director Michael Sardano reported open‑market purchases on November 11, 2025.
He acquired 1,000 shares of common stock at $4.26 held directly. Additional purchases were reported for his spouse of 766 shares at $4.27 and 234 shares at $4.24. Following these transactions, Sardano held 117,839 shares directly. He disclaims beneficial ownership of his spouse’s shares. Sardano serves as President and General Counsel and is also a Director.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
